Component

Barley mixed-linkage beta-(1->3)/(1->4)-glucan

Barley mixed-linkage beta-(1->3)/(1->4)-glucan. Species, exposure and limitations are retained in each linked claim.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Recent data indicated that barley beta-1,3;1,4-glucan given orally potentiated the activity of antitumour monoclonal antibody leading to enhanced tumour regression and survival, and this investigation showed that orally administered yeast beta-1,3;1,6-glucan functioned similarly to barley beta-1,3;1,4-glucan with antitumour monoclonal antibody, with both oral beta-1,3-glucans a requirement for iC3b on tumours and CR3 on granulocytes being confirmed by demonstrating therapeutic failures in mice deficient in C3 or CR3.

    Barley mixed-linkage beta-(1->3)/(1->4)-glucan → Yeast beta-(1->3)/(1->6)-glucan source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    machinery_impairment Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/glucan-research/15240666.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "eaff7297fa40df19ef82e5e1de433ec0cf34590a7e3fda6aa6061e0922666781", "start_char": 0, "end_char": 1454, "text_sha256": "eaff7297fa40df19ef82e5e1de433ec0cf34590a7e3fda6aa6061e0922666781"}
    experimental_model
    Fluorescein-labelled oral glucans tracked through macrophages to marrow, with therapy in C3-deficient and CR3-deficient mice
    exposure
    Orally administered barley beta-1,3;1,4-glucan and orally administered yeast beta-1,3;1,6-glucan, each with antitumour monoclonal antibody
    limitations
    The single experiment in this collection that tested a cereal mixed-linkage glucan and a yeast branched glucan side by side in the same protocol. It is a mouse tumour model, and oral uptake in mice does not establish the same uptake in people.
    nutrient_topic
    Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
    organism
    Mouse
    plain_language
    A cereal glucan and a yeast glucan did the same job by the same route, which is the result that refuses to let the two be filed apart.
    primary_references
    [bg-p15240666] Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. (2004). https://pubmed.ncbi.nlm.nih.gov/15240666/ DOI: 10.4049/jimmunol.173.2.797
    tissue_or_cell_type
    Gut, spleen, lymph node, bone marrow and tumour
    trigger_kind
    machinery_impairment Imported condition classification; unverified.

    Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 242–253

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Fluorescein-labelled oral glucans tracked through macrophages to marrow, with therapy in C3-deficient and CR3-deficient mice · source_derived_draft · unverified_draft

    ### bg-barley-and-yeast-converge Recent data indicated that barley beta-1,3;1,4-glucan given orally potentiated the activity of antitumour monoclonal antibody leading to enhanced tumour regression and survival, and this investigation showed that orally administered yeast beta-1,3;1,6-glucan functioned similarly to barley beta-1,3;1,4-glucan with antitumour monoclonal antibody, with both oral beta-1,3-glucans a requirement for iC3b on tumours and CR3 on granulocytes being confirmed by demonstrating therapeutic failures in mice deficient in C3 or CR3. Condition category: machinery_impairment nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: A cereal glucan and a yeast glucan did the same job by the same route, which is the result that refuses to let the two be filed apart. organism: Mouse tissue_or_cell_type: Gut, spleen, lymph node, bone marrow and tumour experimental_model: Fluorescein-labelled oral glucans tracked through macrophages to marrow, with therapy in C3-deficient and CR3-deficient mice limitations: The single experiment in this collection that tested a cereal mixed-linkage glucan and a yeast branched glucan side by side in the same protocol. It is a mouse tumour model, and oral uptake in mice does not establish the same uptake in people. exposure: Orally administered barley beta-1,3;1,4-glucan and orally administered yeast beta-1,3;1,6-glucan, each with antitumour monoclonal antibody evidence_span: {"source_cache": "artifacts/glucan-research/15240666.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "eaff7297fa40df19ef82e5e1de433ec0cf34590a7e3fda6aa6061e0922666781", "start_char": 0, "end_char": 1454, "text_sha256": "eaff7297fa40df19ef82e5e1de433ec0cf34590a7e3fda6aa6061e0922666781"} [bg-p15240666] Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. (2004). https://pubmed.ncbi.nlm.nih.gov/15240666/ DOI: 10.4049/jimmunol.173.2.797
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. A notable loss of beta-glucan of 0.7 to 2.4 g/d or 13 to 64% was found when intake was compared with excretion, in vitro a higher viscosity development with time for dispersions of oat bread compared with barley bread was noted which could be related to the higher molecular weight of the beta-glucan in this bread, and there seemed to be a depolymerization of the beta-glucan both during bread making and transit through the upper gastrointestinal tract.

    Depolymerisation of a glucan polymer → Molecular weight of a glucan polymer source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/glucan-research/8942412.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9d60ab74209102dfe9e61c4f1a0f45fdc2119c986e385b8174a101f9f98ae3e1", "start_char": 0, "end_char": 1172, "text_sha256": "9d60ab74209102dfe9e61c4f1a0f45fdc2119c986e385b8174a101f9f98ae3e1"}
    experimental_model
    Ileostomy model comparing breads made from oat bran, a barley fraction and wheat flour
    exposure
    Diets based on oat bread, barley bread, wheat bread or oat bread with enzymatically degraded beta-glucan, providing 12.5, 12.9, 1.1 and 4.0 grams per day
    limitations
    Nine ileostomy subjects. The loss is inferred by comparing intake with excretion rather than measured directly as degradation.
    nutrient_topic
    Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
    organism
    Human
    plain_language
    A good deal of the polymer is already broken up by the time the bread is baked, let alone eaten.
    primary_references
    [bg-p8942412] Mixed-linked beta-glucan from breads of different cereals is partly degraded in the human ileostomy model. (1996). https://pubmed.ncbi.nlm.nih.gov/8942412/ DOI: 10.1093/ajcn/64.6.878
    tissue_or_cell_type
    Terminal ileum
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 554–565

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Ileostomy model comparing breads made from oat bran, a barley fraction and wheat flour · source_derived_draft · unverified_draft

    ### bg-bread-making-already-cuts-it A notable loss of beta-glucan of 0.7 to 2.4 g/d or 13 to 64% was found when intake was compared with excretion, in vitro a higher viscosity development with time for dispersions of oat bread compared with barley bread was noted which could be related to the higher molecular weight of the beta-glucan in this bread, and there seemed to be a depolymerization of the beta-glucan both during bread making and transit through the upper gastrointestinal tract. Condition category: biomarker_context nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: A good deal of the polymer is already broken up by the time the bread is baked, let alone eaten. organism: Human tissue_or_cell_type: Terminal ileum experimental_model: Ileostomy model comparing breads made from oat bran, a barley fraction and wheat flour limitations: Nine ileostomy subjects. The loss is inferred by comparing intake with excretion rather than measured directly as degradation. exposure: Diets based on oat bread, barley bread, wheat bread or oat bread with enzymatically degraded beta-glucan, providing 12.5, 12.9, 1.1 and 4.0 grams per day evidence_span: {"source_cache": "artifacts/glucan-research/8942412.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9d60ab74209102dfe9e61c4f1a0f45fdc2119c986e385b8174a101f9f98ae3e1", "start_char": 0, "end_char": 1172, "text_sha256": "9d60ab74209102dfe9e61c4f1a0f45fdc2119c986e385b8174a101f9f98ae3e1"} [bg-p8942412] Mixed-linked beta-glucan from breads of different cereals is partly degraded in the human ileostomy model. (1996). https://pubmed.ncbi.nlm.nih.gov/8942412/ DOI: 10.1093/ajcn/64.6.878
    Complete structured claim and evidence

  2. CR3 serves as the leukocyte beta-glucan receptor through a cation-independent lectin site located C-terminal to the I-domain of CD11b that contains the binding sites for iC3b, ICAM-1 and fibrinogen, a 10-kilodalton soluble zymosan polysaccharide consisting largely of mannose and approximately 5% glucose bound with high affinity of 6.7 x 10(-8) M, binding was blocked not only by pure beta-glucans from yeast, mushroom, seaweed or barley but also by N-acetyl-D-glucosamine and alpha- or beta-methylmannoside and alpha- or beta-methylglucoside, and its sugar specificity is broader than originally appreciated.

    The lectin site of CD11b C-terminal to the I-domain → Beta-glucan source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/glucan-research/8558003.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "00a0fef65e91375066fe9920200032466aec1c0d85bf548d53f64c3d384106b7", "start_char": 0, "end_char": 1936, "text_sha256": "00a0fef65e91375066fe9920200032466aec1c0d85bf548d53f64c3d384106b7"}
    experimental_model
    Flow cytometry with labelled soluble polysaccharides, CR3 and CR4 chimeras, and a panel of domain-specific antibodies
    exposure
    Labelled beta-glucans from yeast, mushroom, seaweed and barley, and a 10-kilodalton soluble zymosan polysaccharide
    limitations
    Binding and inhibition rather than function. The highest-affinity ligand measured was not a pure beta-glucan but a mannose-rich zymosan polysaccharide, and the sugar specificity proved broader than beta-glucan alone.
    nutrient_topic
    Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
    organism
    Human
    plain_language
    The complement receptor grips sugars at a second site, separate from the one that grips the complement fragment.
    primary_references
    [bg-p8558003] Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). (1996). https://pubmed.ncbi.nlm.nih.gov/8558003/ DOI: 10.4049/jimmunol.156.3.1235
    tissue_or_cell_type
    Leukocytes

    Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 203–214

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Flow cytometry with labelled soluble polysaccharides, CR3 and CR4 chimeras, and a panel of domain-specific antibodies · source_derived_draft · unverified_draft

    ### bg-cr3-has-a-lectin-site CR3 serves as the leukocyte beta-glucan receptor through a cation-independent lectin site located C-terminal to the I-domain of CD11b that contains the binding sites for iC3b, ICAM-1 and fibrinogen, a 10-kilodalton soluble zymosan polysaccharide consisting largely of mannose and approximately 5% glucose bound with high affinity of 6.7 x 10(-8) M, binding was blocked not only by pure beta-glucans from yeast, mushroom, seaweed or barley but also by N-acetyl-D-glucosamine and alpha- or beta-methylmannoside and alpha- or beta-methylglucoside, and its sugar specificity is broader than originally appreciated. Condition category: normal nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: The complement receptor grips sugars at a second site, separate from the one that grips the complement fragment. organism: Human tissue_or_cell_type: Leukocytes experimental_model: Flow cytometry with labelled soluble polysaccharides, CR3 and CR4 chimeras, and a panel of domain-specific antibodies limitations: Binding and inhibition rather than function. The highest-affinity ligand measured was not a pure beta-glucan but a mannose-rich zymosan polysaccharide, and the sugar specificity proved broader than beta-glucan alone. exposure: Labelled beta-glucans from yeast, mushroom, seaweed and barley, and a 10-kilodalton soluble zymosan polysaccharide evidence_span: {"source_cache": "artifacts/glucan-research/8558003.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "00a0fef65e91375066fe9920200032466aec1c0d85bf548d53f64c3d384106b7", "start_char": 0, "end_char": 1936, "text_sha256": "00a0fef65e91375066fe9920200032466aec1c0d85bf548d53f64c3d384106b7"} [bg-p8558003] Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). (1996). https://pubmed.ncbi.nlm.nih.gov/8558003/ DOI: 10.4049/jimmunol.156.3.1235
    Complete structured claim and evidence

  3. The applicant proposed a reduction of the lowest effective dose from 4 grams to 2 grams of beta-glucans per 30 grams of available carbohydrates and submitted 21 pertinent published human intervention studies with 59 trial comparisons plus four published systematic reviews and dose-response meta-regression analyses, and in weighing the evidence the Panel considered that the human intervention studies did not consistently show a significant effect of beta-glucans from oats or barley on postprandial glucose incremental area under the curve at doses between 2 and less than 4 grams per 30 grams of available carbohydrates, concluding that a consistent effect has not been demonstrated under the conditions of use proposed.

    Oat mixed-linkage beta-(1->3)/(1->4)-glucan → Postprandial glucose incremental area under the curve source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/glucan-research/40980638.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "ed76af02ac95b48fc5e1dd7e51a6ba51f54b5ba01a7daa7a01ce57bdd9d68bad", "start_char": 0, "end_char": 1864, "text_sha256": "ed76af02ac95b48fc5e1dd7e51a6ba51f54b5ba01a7daa7a01ce57bdd9d68bad"}
    experimental_model
    European Food Safety Authority assessment of a proposal to halve the dose condition on an existing claim
    exposure
    Beta-glucans from oat or barley at doses between 2 and less than 4 grams per 30 grams of available carbohydrates
    limitations
    An assessment of a proposed change to a condition of use, based on 21 studies with 59 trial comparisons plus four published dose-response analyses. A negative conclusion about a proposed lower dose is not a finding that lower doses never act.
    nutrient_topic
    Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
    organism
    Human
    plain_language
    Asked to halve the amount required, the regulator looked at the trials and said the evidence did not hold at that dose.
    primary_references
    [bg-p40980638] Beta-glucans from oats or barley and reduction of postprandial glycaemic responses: Modification of an authorised health claim pursuant to Article 13(1) of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of Regulation (EC) No 1924/2006. (2025). https://pubmed.ncbi.nlm.nih.gov/40980638/ DOI: 10.2903/j.efsa.2025.9630
    tissue_or_cell_type
    Postprandial circulation

    Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 619–630

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · European Food Safety Authority assessment of a proposal to halve the dose condition on an existing claim · source_derived_draft · unverified_draft

    ### bg-the-lower-dose-was-refused The applicant proposed a reduction of the lowest effective dose from 4 grams to 2 grams of beta-glucans per 30 grams of available carbohydrates and submitted 21 pertinent published human intervention studies with 59 trial comparisons plus four published systematic reviews and dose-response meta-regression analyses, and in weighing the evidence the Panel considered that the human intervention studies did not consistently show a significant effect of beta-glucans from oats or barley on postprandial glucose incremental area under the curve at doses between 2 and less than 4 grams per 30 grams of available carbohydrates, concluding that a consistent effect has not been demonstrated under the conditions of use proposed. Condition category: normal nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: Asked to halve the amount required, the regulator looked at the trials and said the evidence did not hold at that dose. organism: Human tissue_or_cell_type: Postprandial circulation experimental_model: European Food Safety Authority assessment of a proposal to halve the dose condition on an existing claim limitations: An assessment of a proposed change to a condition of use, based on 21 studies with 59 trial comparisons plus four published dose-response analyses. A negative conclusion about a proposed lower dose is not a finding that lower doses never act. exposure: Beta-glucans from oat or barley at doses between 2 and less than 4 grams per 30 grams of available carbohydrates evidence_span: {"source_cache": "artifacts/glucan-research/40980638.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "ed76af02ac95b48fc5e1dd7e51a6ba51f54b5ba01a7daa7a01ce57bdd9d68bad", "start_char": 0, "end_char": 1864, "text_sha256": "ed76af02ac95b48fc5e1dd7e51a6ba51f54b5ba01a7daa7a01ce57bdd9d68bad"} [bg-p40980638] Beta-glucans from oats or barley and reduction of postprandial glycaemic responses: Modification of an authorised health claim pursuant to Article 13(1) of Regulation (EC) No 1924/2006 following a request in accordance with Article 19 of Regulation (EC) No 1924/2006. (2025). https://pubmed.ncbi.nlm.nih.gov/40980638/ DOI: 10.2903/j.efsa.2025.9630
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards